Articles related to SURVIVORSHIP

Reevaluation of major hormone therapy studies has prompted renewed discussion about menopause treatment in breast cancer survivors. Emerging interpretation of older trial data suggests treatment risks may vary by patient characteristics and hormone formulation rather than applying uniformly across all populations.

A case of chemotherapy-induced menopause left unmanaged for six years prompted a physician’s pointed critique of survivorship care failures, highlighting the clinical and legal stakes of untreated premature ovarian insufficiency following gonadotoxic therapy.

“The extended-hours model was effective… early morning dose, in-center observation, overnight remote monitoring equipment, and next-day follow-up cut the need for extended shifts and differential pay.”

A retrospective analysis of more than 840,000 patients with breast cancer found lower all-cause mortality and reduced recurrence risk among those with obesity or type 2 diabetes who received GLP-1 receptor agonists compared with similar patients who did not, though the study did not establish causation.

Retrospective analysis of pediatric cancer survivors identified low overall CHIP prevalence, with antimetabolite therapy and methotrexate exposure emerging as the strongest treatment-associated signals.

The current real-world cohort study examines long-term survival outcomes in the 5 years after a COVID-19 hospitalization for adults with a solid malignancy. The study assessed the impact of vaccination status, vaccine platform, primary tumor site, and cancer treatment.